Healthy Patients
Conditions
Brief summary
The role of the pulmonary microbiome in the pathophysiology of lung disease is becoming increasingly well understood. Studies on murine models have highlighted the immunomodulatory and antibacterial activity of certain commensal bacteria, such as S. mitis, and have led to an understanding of their potential therapeutic impact. The investigators will therefore couple their analyses of the respiratory microbiome with an in-depth analysis of mucosal immunity. In particular, they will characterize immune cell types and frequencies using high-dimensional (spectral) flow cytometry and single cell RNA-sequencing. Finally, they will study the mediators exchanged between the microbiome and the host using proteomic and metabolomic analyses of respiratory fluids.
Interventions
OTHERVoluntary
Subjects undergoing scheduled surgery in the operating room at Nantes University Hospital, requiring general anesthesia with placement of an endotracheal intubation tube for invasive mechanical ventilation.
Sponsors
Nantes University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or female. * Age from 18 to 70. * Indication for scheduled general anesthesia with orotracheal intubation for non-thoracic, non-carcinological, non-septic surgical procedures such as prosthesis (knee or hip), spinal surgery, digestive hernia surgery, gall bladder surgery, maxillofacial surgery (non-exhaustive list). * Membership of a social security scheme or beneficiary of such a scheme. * Written informed consent.
Exclusion criteria
* Persons under guardianship or trusteeship. * Pregnant or breast-feeding woman. * Antibiotic treatment received within 28 days prior to surgery, regardless of the site of infection. * Acute respiratory pathology within the last 28 days (pneumothorax, bronchitis or pneumonia including Covid). * History of chronic respiratory disease (asthma, chronic obstructive pulmonary disease, emphysema, lung cancer, cystic fibrosis, etc.). * Immunosuppression (cancer active or within the last 5 years, HIV, radio-chemotherapy within the last year, organ transplant). * Chronic inflammatory disease (digestive, osteoarticular, neurological or cutaneous) requiring or having required specific treatment in the last 12 months. * Type I or II diabetes. * Steroid treatment within the last 30 days (regardless of dose or duration).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Atlas of host-microbiome interactions | 1 day | Healthy respiratory metacluster |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlations between bacterial species | Day 1 | To define the link between the patient and the bacterial transcriptional activities |
| Correlations between cell populations | Day 1 | To define the link between the patient and the transcriptional clusters of cell populations |
| Correlations between metabolite concentrations | Day 1 | To define the link between the patient and the metabolite concentrations |
| Correlations between protein concentrations | Day 1 | To define the link between the patient and the protein concentrations |
| Correlations between host-microbiome interactions and quality of life scales | Day 1 | To define the link between the patient and different scales (MOCA, EPICES, modified MRC, NYHA, EQ5D-5L, SWLS, SF-36, HADS and BPI |
Countries
France
Outcome results
None listed